Biotricity, Inc. (BTCY): ANSOFF MATRIX [Dec-2025 Updated]

You're looking at the growth blueprint for Biotricity, Inc. (BTCY) right now, and the numbers from fiscal year 2025 are solid: $13.8 million in revenue with a healthy 76.6% gross margin, showing their Technology-as-a-Service (TaaS) model is working. Honestly, the real question isn't if they can grow, but how aggressively, especially with that new AI capability they're pushing. We've mapped out their four core paths-from doubling down on existing hospital clients and targeting PCPs to eyeing new international markets, developing that next-gen device, and even exploring data monetization-to see exactly where the smartest capital deployment lies for the next phase. That's the whole game plan, laid out below.

Biotricity, Inc. (BTCY) - Ansoff Matrix: Market Penetration

You're looking at how Biotricity, Inc. (BTCY) can drive more revenue from its existing customer base-the core of Market Penetration. This is about getting more utilization from the hospitals and clinics already using Bioflux™ and Biotres.

The first action is deep penetration within the existing hospital footprint. The goal is to expand utilization of Bioflux™ and Biotres within the 90% of US hospitals covered by GPO alliances. This isn't about signing new GPO contracts, but ensuring that once the contract is in place, the devices are fully integrated and used across more departments or patient cohorts within those covered facilities. Think of it as maximizing the installed base.

A key lever here is the revenue model shift. You want to increase recurring Technology Fees, which hit $12.6 million in FY2025, by upselling existing customers to flat-fee models. This move directly impacts revenue quality and predictability. For context, in Q3 FY2025, Technology Fees were $3.39 million, making up 94% of total revenue. The flat-fee SaaS component reached 67% of those Technology Fees in Q3 FY2025, showing the transition is underway but still has room to run.

Here are the key metrics underpinning this strategy:

Next, you need to broaden the clinical use case. You must target primary care physicians (PCPs) for remote patient monitoring (RPM) adoption, moving beyond just cardiology specialists. While Bioflux and Biotres were initially designed for cardiologists, expanding into PCP workflows for chronic condition management, like atrial fibrillation detection, opens up a much larger segment of the market. This is about increasing the breadth of use within existing accounts.

To accelerate the revenue quality, you need to run targeted campaigns to convert remaining usage-based customers to the higher-quality, predictable flat-fee subscription model. This directly addresses the remaining 33% of Technology Fees that were not on the flat-fee structure as of Q3 FY2025. Every conversion here lowers the risk associated with variable utilization and locks in future revenue.

Finally, you leverage the stickiness of the service. You should leverage the high customer retention rate, reported at approximately 99%, to drive peer-to-peer referrals within hospital networks and clinics. When a department head sees a colleague in an adjacent network achieve better workflow efficiency or revenue capture-perhaps fivefold compared to existing solutions-they are more likely to adopt. Referrals from trusted peers are the cheapest and most effective form of sales in this environment.

The focus here is on density, not just footprint. You're mining the existing customer base for more recurring dollars.

Biotricity, Inc. (BTCY) - Ansoff Matrix: Market Development

Accelerate commercialization in international markets where regulatory clearance is secured, like Canada, Saudi Arabia, and Argentina.

Biotricity, Inc. secured Health Canada clearance for Biotres on February 29, 2024. The company is actively pursuing expansion, evidenced by its overall growth trajectory, with Fiscal Year 2025 revenue reaching $13.8 million, a 14.3% year-over-year increase.

Enter the new vertical of payor contracts, focusing on value-based and managed care programs in the US.

Biotricity, Inc. has forged a strategic partnership focused on payor contracts for value based and managed care programs, marking a new vertical for the Company. This aligns with industry trends, where a significant segment, 30%, of surveyed organizations report having a quarter of their revenue tied to Value-Based Care (VBC) contracts. The company is also expanding its market presence with contracts with the VA and leading home care groups as of the second quarter of Fiscal Year 2026.

Prioritize opportunistic expansion into key European markets, specifically Germany, through local distribution partnerships.

The company is focused on expanding its geographic footprint, serving thousands of cardiologists across hundreds of centers. Strategic alliances forged during fiscal 2025 and 2026 have positioned Biotricity, Inc. to capitalize on expansive market channels.

Target large-scale employer health plans and government health systems outside of the current hospital-centric model.

Strategic alliances have positioned Biotricity, Inc. to gain access to approximately 90% of all hospitals in America. This is built upon earlier milestones, including securing 3 Group Purchasing Organization (GPO) partnerships covering 87% of US Hospitals (as of June 2024). The company currently has its solutions used by hundreds of centers across 35 states.

Utilize the Biocare Telemed™ platform to reach underserved rural US markets with remote diagnostic services.

The company is committed to revolutionizing medical diagnostics and consumer healthcare. Biotricity, Inc. achieved a gross profit percentage of 81.9% in the second quarter of Fiscal Year 2026, an improvement of 660 basis points from 75.3% in the prior year quarter. Recurring technology fees comprised 94% of total revenue in the third quarter of Fiscal Year 2025.

Here's a quick math on the financial progress supporting this market development:

The negative EBITDA for Fiscal Year 2025 was reduced by $5.7 million, representing an improvement of 63.9%. For the fourth quarter of Fiscal Year 2025, the company reported its first-ever positive Adjusted EBITDA of $438,260.

Biotricity, Inc. (BTCY) - Ansoff Matrix: Product Development

You're looking at how Biotricity, Inc. (BTCY) plans to grow by making new things for the market it already serves. This is all about building out the technology platform to increase the value captured from the existing customer base, which is heavily weighted toward recurring revenue.

The core of this strategy involves the Cardiac AI Cloud platform. As of the first quarter of fiscal 2026 (ended June 30, 2025), this platform was leveraging over 2 trillion beats of anonymized data. The company remains on track to pursue FDA clearance for its groundbreaking AI clinical model in the coming months following the fiscal year 2025 results. This model is designed to distill important information to support clinicians, aiming to enhance diagnostic accuracy and marketability. The overall healthcare AI market is projected to reach $208.2 billion by 2030.

For the existing customer base, the focus is on upgrading and expanding device utility. The rapid adoption of the next-generation cardiac monitoring device, Biocore Pro, is validating Biotricity, Inc.'s ability to scale its technology and impact. Furthermore, the company is making progress toward filing for FDA approval for the Biocore Pro 2 cardiac monitor by the end of Q1 next year. This upgrade path supports the strong recurring revenue stream; for fiscal year 2025 (ended March 31, 2025), recurring Technology Fees grew 12% year-over-year to $12.6 million, representing over 10.5 times device sales revenue.

Developing new software features is intrinsically linked to the data advantage. Biotricity, Inc.'s focus is expanding data capabilities to develop predictive analytics for early detection of cardiac conditions. This development is fueled by the massive dataset collected; as of the end of fiscal year 2025, the company had monitored and recorded over 1 trillion heartbeats. The company is continuing to expand its automation engine alongside the development of this clinical engine.

Seamless workflow is a key component for adoption, which means integrating the platform into the daily routine of clinicians. While specific integration statistics aren't available, the company is focused on delivering a comprehensive suite of diagnostic tools that empower clinicians with deeper, more accessible insights. This effort supports the overall financial health, as demonstrated by the fiscal year 2025 results where operating expenses were reduced by 24.5% to $13 million.

Extending the service window moves Biotricity, Inc. into post-diagnostic and chronic care management. The company is actively reforming the market by bridging the gap in remote monitoring and chronic care management, offering both diagnostic and post-diagnostic solutions. A clear action here is the strategic entry into new verticals; the company forged a partnership focused on payor contracts for value based and managed care programs during fiscal 2025, which are new verticals for Biotricity, Inc.. This diversification is also seen in the strategic entry into adjacent fields such as sleep and pulmonology to reinforce its position in connected healthcare.

Here are the key financial metrics from the most recent fiscal year that underpin this product development investment:

The company's focus on technology fees is clear, as these fees comprised 94% of total revenue in Q3-FY25, with an 81.4% gross profit percentage for that segment. The Q2-FY26 recurring (TaaS) Technology Fees rose to $3.5 million, representing 88.7% of total revenue for that quarter.

The Product Development strategy is supported by a strong market access position, with strategic alliances giving access to approximately 90% of all hospitals in America.

• Secure FDA clearance for the groundbreaking Cardiac AI clinical model.
• Roll out the next-generation cardiac monitoring device, Biocore Pro, for upgrade revenue.
• Integrate the Cardiac AI Cloud platform with third-party Electronic Health Records (EHRs).
• Develop new software features for existing devices, like enhanced predictive analytics.
• Launch a post-diagnostic, long-term chronic care management solution.

Finance: review the capital allocation plan for the Biocore Pro 2 FDA submission timeline by end of Q4 2025.

Biotricity, Inc. (BTCY) - Ansoff Matrix: Diversification

You're looking at how Biotricity, Inc. (BTCY) can move beyond its core cardiac monitoring to capture new revenue streams. The financial foundation for this push is solidifying; for the fiscal year ended March 31, 2025 (FY25), revenue grew 14.3% year-over-year to $13.8 million. Gross margin improved by 8.9% to reach 76.6% in FY25, up from 69.3% the prior year.

The company is already showing strong operational leverage, with FY25 operating expenses lower by 24.5% YOY. This efficiency is translating to the bottom line, as evidenced by the second quarter of fiscal 2026 (Q2-FY26, ended September 30, 2025) showing an EBITDA of $373,000. The recurring revenue stream is the engine here; in FY25, recurring Technology Fees rose 12% to $12.6 million, which is more than 10.5 times the revenue from device sales.

Here are the specific diversification vectors Biotricity, Inc. is positioned to pursue:

• Expand the TaaS platform into adjacent remote monitoring areas, such as respiratory or neurological conditions.
• Develop a new, non-cardiac consumer-focused wearable device for lifestyle management, separate from the medical-grade Bioflux.
• Acquire a smaller, complementary med-tech company with established products in a new chronic disease vertical.
• Monetize the extensive, anonymized patient data set by creating a new data-as-a-service offering for pharmaceutical or research partners.
• Form a joint venture to offer a full-stack, end-to-end remote care solution for a specific comorbidity like diabetes management.

The move into neurological conditions is supported by existing groundwork. Biotricity, Inc. has announced a partnership to conduct cardiac screenings in patients with neurological issues, a market segment comprised of over 100 million Americans suffering from at least 1 neurological issue. Furthermore, the company's IP portfolio is advancing this capability, with 15 issued patents and an additional 14 patents pending focused on a multi-biometric device platform capable of functioning as both a patch and a watch.

Monetizing data is a clear path, given the scale already achieved. Biotricity, Inc. has already monitored and recorded well over 2 trillion heartbeats. The company's Cardiac AI Cloud platform is set to leverage this anonymized data. The recurring revenue model is already dominant, with Q2-FY26 technology fees accounting for 89% of the quarter's total revenue of $3.9 million.

The financial trajectory supports investment in these new areas. For Q2-FY26, revenue grew 19% year-over-year to $3.9 million, and the gross profit percentage expanded 660 basis points to 81.9%. The company is also strategically positioned for faster market access through partnerships, having established relationships with Group Purchasing Organizations (GPOs) covering 90% of US hospitals.

Here is a snapshot of the financial performance underpinning the diversification strategy:

The focus on operational efficiency is clear, as the negative EBITDA for FY25 was reduced by $5.7 million to $3.2 million. This disciplined approach is key as Biotricity, Inc. explores new verticals, such as the potential joint venture for a comorbidity like diabetes management, leveraging its platform that already has FDA and HIPAA compliant device OS, Cloud, Big Data, and AI components.

Finance: draft FY2026 projected cash flow incorporating a 19% revenue growth rate for the next two reported quarters by Monday.